KR20170072366A - 재활성화를 예방하기 위한 결핵 백신 - Google Patents

재활성화를 예방하기 위한 결핵 백신 Download PDF

Info

Publication number
KR20170072366A
KR20170072366A KR1020177016378A KR20177016378A KR20170072366A KR 20170072366 A KR20170072366 A KR 20170072366A KR 1020177016378 A KR1020177016378 A KR 1020177016378A KR 20177016378 A KR20177016378 A KR 20177016378A KR 20170072366 A KR20170072366 A KR 20170072366A
Authority
KR
South Korea
Prior art keywords
ala
gly
leu
pro
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177016378A
Other languages
English (en)
Korean (ko)
Inventor
제스 디트리히
피터 안데르센
커리너 빙스보 런드버그
트룩 티 킴 댄 호앙
Original Assignee
스태튼스 세룸 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스태튼스 세룸 인스티튜트 filed Critical 스태튼스 세룸 인스티튜트
Publication of KR20170072366A publication Critical patent/KR20170072366A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020177016378A 2009-04-24 2010-04-23 재활성화를 예방하기 위한 결핵 백신 Ceased KR20170072366A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24
DKPA200900539 2009-04-24
PCT/DK2010/000054 WO2010121618A1 (en) 2009-04-24 2010-04-23 A tuberculosis tb vaccine to prevent reactivation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028104A Division KR20120014176A (ko) 2009-04-24 2010-04-23 재활성화를 예방하기 위한 결핵 백신

Publications (1)

Publication Number Publication Date
KR20170072366A true KR20170072366A (ko) 2017-06-26

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177016378A Ceased KR20170072366A (ko) 2009-04-24 2010-04-23 재활성화를 예방하기 위한 결핵 백신
KR1020117028104A Ceased KR20120014176A (ko) 2009-04-24 2010-04-23 재활성화를 예방하기 위한 결핵 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117028104A Ceased KR20120014176A (ko) 2009-04-24 2010-04-23 재활성화를 예방하기 위한 결핵 백신

Country Status (17)

Country Link
US (2) US9074001B2 (https=)
EP (1) EP2421557B1 (https=)
JP (2) JP5839361B2 (https=)
KR (2) KR20170072366A (https=)
CN (2) CN102413837B (https=)
AU (1) AU2010238943B9 (https=)
BR (1) BRPI1006452A2 (https=)
CA (1) CA2759583C (https=)
DK (1) DK2421557T3 (https=)
ES (1) ES2714383T3 (https=)
HK (1) HK1204549A1 (https=)
IL (1) IL215591A (https=)
MX (2) MX2011011186A (https=)
PL (1) PL2421557T3 (https=)
TR (1) TR201903223T4 (https=)
WO (1) WO2010121618A1 (https=)
ZA (1) ZA201108564B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230100972A (ko) * 2021-12-29 2023-07-06 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
KR20250082868A (ko) 2023-11-30 2025-06-09 서울대학교산학협력단 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
PL2661253T3 (pl) * 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
DK2802345T3 (en) 2012-01-12 2018-04-30 Archivel Farma Sl MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
JP6470179B2 (ja) * 2012-10-23 2019-02-13 スタテンス セールム インスティトゥート 結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
KR20150127587A (ko) * 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 결핵의 예방 또는 치료를 위한 합성 면역원
AU2014365971B2 (en) * 2013-12-16 2021-02-04 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
WO2015104380A1 (en) * 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CA3098015A1 (en) 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用
CN120192426B (zh) * 2025-03-04 2025-11-11 江西澄实生物科技有限公司 一种预防沙门氏菌感染的疫苗及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US20060040332A1 (en) * 2004-06-17 2006-02-23 Beckman Coulter Mycobacterium tuberculosis epitopes and methods of use thereof
KR20070091620A (ko) * 2004-11-16 2007-09-11 크루셀 홀란드 비.브이. 재조합 바이러스 벡터를 포함하는 다가 백신
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
PT832093E (pt) 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
JP5010079B2 (ja) 1999-07-13 2012-08-29 スタテンズ セーラム インスティテュート マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
ATE535600T1 (de) * 2002-04-05 2011-12-15 Pasteur Institut Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
BRPI0606165A2 (pt) 2005-01-05 2009-06-02 Isis Innovation método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
BRPI0612833A2 (pt) 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US20040057963A1 (en) * 2002-07-13 2004-03-25 Peter Andersen Therapeutic TB vaccine
US20060040332A1 (en) * 2004-06-17 2006-02-23 Beckman Coulter Mycobacterium tuberculosis epitopes and methods of use thereof
KR20070091620A (ko) * 2004-11-16 2007-09-11 크루셀 홀란드 비.브이. 재조합 바이러스 벡터를 포함하는 다가 백신
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Infect. Immun. 74(1): 88-98(2006.01.) *
Tuberculosis 89(2): 142-148 (2009.03.04.) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230100972A (ko) * 2021-12-29 2023-07-06 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
KR20250082868A (ko) 2023-11-30 2025-06-09 서울대학교산학협력단 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도

Also Published As

Publication number Publication date
US20120039925A1 (en) 2012-02-16
KR20120014176A (ko) 2012-02-16
HK1166018A1 (zh) 2012-10-19
IL215591A (en) 2016-03-31
EP2421557B1 (en) 2018-12-05
JP2015199771A (ja) 2015-11-12
CN104107425B (zh) 2018-07-17
PL2421557T3 (pl) 2019-07-31
MX2011011186A (es) 2012-02-13
US20150093407A1 (en) 2015-04-02
DK2421557T3 (en) 2019-03-25
ES2714383T3 (es) 2019-05-28
MX370744B (es) 2019-12-20
BRPI1006452A2 (pt) 2016-12-27
WO2010121618A1 (en) 2010-10-28
HK1204549A1 (en) 2015-11-27
AU2010238943B9 (en) 2015-10-15
US9074001B2 (en) 2015-07-07
CA2759583A1 (en) 2010-10-28
JP6215260B2 (ja) 2017-10-18
CN102413837B (zh) 2015-11-25
EP2421557A1 (en) 2012-02-29
JP2012524733A (ja) 2012-10-18
CN104107425A (zh) 2014-10-22
AU2010238943A1 (en) 2011-11-03
AU2010238943A9 (en) 2015-10-15
IL215591A0 (en) 2011-12-29
EP2421557A4 (en) 2013-03-13
CN102413837A (zh) 2012-04-11
JP5839361B2 (ja) 2016-01-06
US10519202B2 (en) 2019-12-31
TR201903223T4 (tr) 2019-03-21
ZA201108564B (en) 2018-11-28
AU2010238943B2 (en) 2015-09-17
CA2759583C (en) 2020-06-16

Similar Documents

Publication Publication Date Title
DK2421557T3 (en) TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
EP1523331B1 (en) Therapeutic tb vaccine
AU2006261445B2 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2005061534A2 (en) Improved tuberculosis vaccines
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
HK1166018B (en) A tuberculosis tb vaccine to prevent reactivation
AU2013206297A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170614

Application number text: 1020117028104

Filing date: 20111124

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170819

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180211

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170819

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180211

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171019

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180605

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180514

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180211

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171019

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170819

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20180806

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180605

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180211

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20191121

Appeal identifier: 2018101003312

Request date: 20180806

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101003312; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180806

Effective date: 20191121

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191121

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180806

Decision date: 20191121

Appeal identifier: 2018101003312

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2020201001465; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20191121

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210115

Appeal identifier: 2020201001465

Request date: 20200121

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2020201001465; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200121

Effective date: 20210115

PJ1302 Judgment (patent court)

Patent event date: 20210118

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20200121

Decision date: 20210115

Appeal identifier: 2020201001465

Appeal kind category: Appeal against decision to decline refusal